Is amikacin monotherapy appropriate for a multidrug‑resistant Acinetobacter baumannii urinary tract infection that is susceptible to amikacin and gentamicin?

Amikacin Monotherapy for MDR Acinetobacter baumannii UTI

For a non-severe urinary tract infection caused by multidrug-resistant Acinetobacter baumannii that is susceptible to amikacin and gentamicin, amikacin monotherapy is appropriate and recommended. 1

Clinical Reasoning

The most recent ESCMID guidelines (2022) provide clear direction on this scenario. For patients with non-severe or low-risk carbapenem-resistant Acinetobacter baumannii (CRAB) infections, monotherapy chosen from among in vitro active "old drugs" (including aminoglycosides like amikacin) is considered good clinical practice, selected on an individual basis according to the source of infection. 1

Key Decision Points

Severity Assessment is Critical:

• If this is a non-severe UTI (no sepsis, hemodynamic stability, no ICU admission): Monotherapy with amikacin is appropriate 1
• If this is a severe infection (sepsis, ICU patient, high-risk): Combination therapy with two in vitro active drugs is suggested 1

Why Monotherapy Works for UTI

Urinary tract infections represent a favorable scenario for monotherapy because:

• Aminoglycosides achieve excellent urinary concentrations far exceeding serum levels
• The organism is documented susceptible to amikacin
• UTIs are generally considered lower-risk infections compared to pneumonia or bloodstream infections
• The FDA label confirms amikacin is indicated for serious infections caused by susceptible Acinetobacter species 2

Dosing Considerations

For amikacin in MDR Acinetobacter infections:

• Standard dosing: 15-20 mg/kg/day (though specific UTI dosing may vary)
• Monitor renal function closely given aminoglycoside nephrotoxicity risk
• Therapeutic drug monitoring recommended for prolonged courses

Important Caveats

Do NOT use monotherapy if:

• Patient is severely ill or septic → use combination therapy 1
• Patient is in ICU with high-risk infection → use combination therapy 1
• Infection is pneumonia/VAP → combination strongly preferred 3
• Patient has bacteremia → consider combination therapy 1

Combination therapy considerations:

• The 2015 ICU guidelines specifically note that for severe and high-risk CRAB infections, combination therapy including two in vitro active antibiotics is suggested 3
• However, recent evidence shows no mortality benefit from combination therapy over monotherapy in most settings 4, 5, 6, though microbiological clearance may be faster
• The lack of clinical benefit from combinations appears related to host factors dominating outcomes in severe infections 5

Antibiotic Stewardship Perspective

Monotherapy is preferred when appropriate because:

• Reduces unnecessary antibiotic exposure
• Decreases toxicity risk (particularly nephrotoxicity from polymyxin combinations)
• Preserves other agents like colistin for more severe infections 3
• Recent systematic reviews show no compelling evidence that combination therapy improves clinical outcomes for most MDR Acinetobacter infections 7, 5

Alternative Consideration

If the organism's sulbactam MIC is ≤4 mg/L, sulbactam-based therapy may be preferable to aminoglycosides given its better safety profile and comparable efficacy 3. However, this requires specific susceptibility testing that may not be routinely available.

Bottom line: For non-severe MDR Acinetobacter baumannii UTI with documented amikacin susceptibility, monotherapy is appropriate and follows current guideline recommendations. Escalate to combination therapy only if the patient deteriorates or has severe/high-risk features.